the Hornsey pharmaceutical
been dubbed the new A-share “brain tumor drug stocks” yesterday the word limit. Although the company made a clarification announcement said owned subsidiary of U.S. pharmaceutical companies Kinex Corporation to jointly develop anti-brain tumor drug KX02 there are many uncertainties in the pre-clinical studies, clinical research, pharmaceuticals reporting and marketing stage, even if progress smoothly, and the final completion of the development of new drugs also need 5 – 6 years.
However, the market does not care about the potential risks. Industry experts believe that the KX02 project on the Hornsey pharmaceutical performance impact of unpredictable circumstances, speculation A Shares “shares” of the brain tumor drug risky.
Hornsey confirm the development of anticancer drugs
Hornsey pharmaceutical clarification announcement yesterday its holding subsidiary, Guangzhou City, Hornsey Drug Development Co., Ltd. and K inex company already signed the KX 02 “license agreement” as early as May 6 this year. The agreement, K the inex Company License Hornsey aspects related rights price of $ 6 million. The two sides will set up according to the the KXO 2 projects in the U.S. and China to declare the process of new drugs and the stage results a milestone in the project in stages and gradually pay.It is reported that
, K, X02 K, inex companies own R & D, is a lipophilic, antineoplastic agents with dual inhibition of src kinase / pretubulin, the animal experiments prove that the KX 02, including malignant gliomas can effectively inhibit a series of brain tumor cells, including cell lines. K X02 project in the United States has been completed according to the FD A requirements of the pre-clinical experiments, reported in mid-August 2012, the FD A IN D applications, IN D, approved to carry out a clinical study. This project in China is still in technical due diligence stage. (Source: Southern Metropolis Daily, Southern Network)
the Hornsey pharmaceutical CEO WANG Yong-hui had given to the foreign media say: “This cooperation is an important strategic decision on Hornsey, and help to further expand our R & D portfolio of small molecule drugs.”
accordance with the K inex company’s statement, the pharmacokinetic studies have shown that the KX 02 oral absorption, and 76% of the penetration of plasma brain tissue. Mechanism study shows that only lead to surface necrosis compared to temozolomide, the KX 02 also can be reached inside the tumor, causing inside the tumor necrosis.
However, domestic new drug research and development specialists claimed in an interview with the Southern Reporter: “preclinical animal experimental data on the human body does not necessarily have the same result.”
The experts also believe that, KX 02 competing products temozolomide now the United States and the European medical community assessed the “gold standard” for treatment of malignant brain tumors. The international medical community has temozolomide as first-line drugs to treat malignant brain tumors. K X-02 and there will be competition for Mo acetazolamide no small difficulty.
in China, the KX 02 even if successfully developed, market development, the situation is not optimistic. At present, oral temozolomide often release formulations (limited to second-line drugs) has been included in the national health insurance B directory. Multinational pharmaceutical company Schering-Plough and Tasly and double-Heron Pharmaceutical temozolomide layout. Among them, Tasly and double-heron also holds the for MO acetazolamide drug substance and capsules license.the
Manhattan Capital Management Consulting Co., Ltd. President Wang Jin told reporters, foreign drug development companies and domestic pharmaceutical companies to develop new drugs on the rise, but so far have not really had a precedent. “The research and development of anticancer drugs usually need to do in stage Ⅰ, Phase II, III Phase IV clinical trials, Ⅰ, clinical project, the risk of failure as much as 90 percent.” Wang says.the
to be wary of heavy beer lesson
Hornsey pharmaceutical listed since
performance has been less than ideal. Dragged down by the performance, $ 4.8 billion of its market value has been closed from the first day of December 2011, plummeted to less than $ 2.4 billion in June 8, 2012, shrinking more than half.In order to change the product structure of a single risk, last year, Hornsey pharmaceutical has raised funds over the Guangdong nine biotechnology companies, part of the assets of the state pharmaceutical companies, pharmaceutical companies in Guangdong Qingping, Zhongshan Yoplait biotech companies 90% equity income in the bag. However, after the big acquisitions diversified scene, did not produce much income. view
in 2012, the pharmaceutical sector, such as Chongqing Beer and other “black swan” event, a securities company in Shanghai pharmaceutical industry analyst at Hornsey pharmaceuticals to enter the field of cancer drugs also appeared to be quite cautious, in her view : “Unless the KX 02 in subsequent human clinical trials can confirm a specific treatment effect on brain tumor cells, and can finally listed, otherwise, the KX 02 projects Hornsey pharmaceutical significance.”
NetEase statement: NetEase reproduced above for the purpose of transferring more information that confirmed the description or agree with their views. The article content is for reference only and does not constitute investment advice. Investors pursuant to operate your own risk.
Securities News – the NetEase Channel